Thermo Fisher Scientific (Massachusetts, USA) will acquire Life Technologies Corporation (California, USA) under the terms of a definitive agreement signed earlier this week.
Thermo Fisher Scientific (Massachusetts, USA) will acquire Life Technologies Corporation (California, USA) under the terms of a definitive agreement signed earlier this week.
The deal is estimated to be $76.00 a share at a total cost of $13.6 billion. The transaction was reportedly approved by both of the company’s board of directors, according to a press release.
Life Technologies is a global biotechnology company, and is recognized as a leading player in the development of sequencing technology. The acquisition will place Thermo Fisher as a key competitor in the development of advanced genetic testing, the potential key to personalized medicine.
“We are extremely excited about this transaction because it creates the ultimate partner for our customers and significant value for our shareholders,” said Marc N. Casper, President and CEO of Thermo Fisher Scientific.
Gregory T. Lucier, Chairman and CEO of Life Technologies, commented, “This transaction brings together two companies intent on accelerating innovation for our customers and achieving greater success in a highly competitive global industry.”
Lucier added: “This combination delivers immediate and significant cash value to our stockholders and represents a successful conclusion to the board’s strategic review to enhance stockholder value and develop an even stronger future for Life Technologies.”
For more information please visit:
www.lifetechnologies.com
or
www.thermoscientific.com
This story originally appeared in The Column. Click here to view that issue.
Separation Science Spotlight: What’s in Store for Chromatographers at Pittcon
February 25th 2025In this video interview, Emanuela Gionfriddo, Daniel Armstrong, and Nicholas Snow preview their talks at Pittcon, as well as give their opinions about what topics they hope to explore more at the conference.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.